Midatech's investigational glioblastoma treatment gets Fast Track status
marketwatch.com
news
2022-06-01 13:14:14

U.S.-listed shares of Midatech Pharma PLC ADR MTP, +0.03% MTPH, soared 35.7% in premarket trading on Wednesday after the company said the Food and Drug Administration granted Fast Track status to the treatment it's developing for recurrent glioblastoma, a fast-growing brain tumor. Midatech's stock is down 40.3% this year, while the S&P 500 SPX, -0.63% has declined 13.3%.
